Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 12

Results: 21

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8+ T‑cells from GzmB mediated self‑destruction.

Published in:

2022

By:

Zangari, Brendan;
Tsuji, Takemasa;
Matsuzaki, Junko;
Mohammadpour, Hemn;
Eppolito, Cheryl;
Battaglia, Sebastiano;
Ito, Fumito;
Chodon, Thinle;
Koya, Richard;
Robert McGray, A. J.;
Odunsi, Kunle

Publication type:

Correction Notice

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3071, doi. 10.1007/s00262-022-03224-2

By:

Chen, Haizhu;
Feng, Yu;
Zhou, Yu;
Tao, Yunxia;
Tang, Le;
Shi, Yuankai

Publication type:

Article

Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3057, doi. 10.1007/s00262-022-03223-3

By:

Li, Xiang;
Zhai, Jing;
Shen, Yuke;
Zhang, Tiancheng;
Wang, Yaohui;
He, Yani;
You, Qiang;
Shen, Lizong

Publication type:

Article

High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3013, doi. 10.1007/s00262-022-03222-4

By:

Han, Myung-Hoon;
Min, Kyueng-Whan;
Noh, Yung-Kyun;
Kim, Jae Min;
Cheong, Jin Hwan;
Ryu, Je Il;
Won, Yu Deok;
Koh, Seong-Ho;
Myung, Jae Kyung;
Park, Ji Young;
Kwon, Mi Jung

Publication type:

Article

Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3029, doi. 10.1007/s00262-022-03220-6

By:

Lee, Sung Eun;
Jang, Gun-Young;
Lee, Ji won;
Park, Sang Hyeon;
Han, Hee Dong;
Park, Yeong-Min;
Kang, Tae Heung

Publication type:

Article

Functional expression of CD73 on human natural killer cells.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3043, doi. 10.1007/s00262-022-03219-z

By:

Chambers, Andrea M.;
Wang, Jiao;
Dao, Tram N.;
Lupo, Kyle B.;
Veenhuis, Paige;
Ayers, Mitchell G.;
Slivova, Veronika;
Cohen-Gadol, Aaron A.;
Matosevic, Sandro

Publication type:

Article

Natural killer cells and acute myeloid leukemia: promises and challenges.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2849, doi. 10.1007/s00262-022-03217-1

By:

Rahmani, Shayan;
Yazdanpanah, Niloufar;
Rezaei, Nima

Publication type:

Article

Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3093, doi. 10.1007/s00262-022-03208-2

By:

Palassin, Pascale;
Maria, Alexandre T. J.;
Ladhari, Chayma;
Quantin, Xavier;
Montani, David;
Bourdin, Arnaud;
Boissin, Clément;
Fesler, Pierre;
Hillaire-Buys, Dominique;
Guilpain, Philippe;
Faillie, Jean-Luc

Publication type:

Article

Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3099, doi. 10.1007/s00262-022-03216-2

By:

Moriya, Taiki;
Hashimoto, Mayuko;
Matsushita, Hina;
Masuyama, Shion;
Yoshida, Rina;
Okada, Ryuhei;
Furusawa, Aki;
Fujimura, Daiki;
Wakiyama, Hiroaki;
Kato, Takuya;
Choyke, Peter L.;
Kusumoto, Yutaka;
Chtanova, Tatyana;
Kobayashi, Hisataka;
Tomura, Michio

Publication type:

Article

Targeting tumor extracellular matrix activates the tumor-draining lymph nodes.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2957, doi. 10.1007/s00262-022-03212-6

By:

Najibi, Alexander J.;
Shih, Ting-Yu;
Zhang, David K. Y.;
Lou, Junzhe;
Sobral, Miguel C.;
Wang, Hua;
Dellacherie, Maxence O.;
Adu-Berchie, Kwasi;
Mooney, David J.

Publication type:

Article

Checkpoint-inhibitor induced Polyserositis with Edema.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 3087, doi. 10.1007/s00262-022-03211-7

By:

Zierold, Sarah;
Akcetin, Larissa Semra;
Gresser, Eva;
Maier, Anna Marie;
König, Alexander;
Kramer, Rafaela;
Theurich, Sebastian;
Tomsitz, Dirk;
Erdmann, Michael;
French, Lars E.;
Rudelius, Martina;
Heinzerling, Lucie

Publication type:

Article

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2943, doi. 10.1007/s00262-022-03210-8

By:

Varghese, Bindu;
Lynch, Lydia;
Vriend, Lianne E.;
Draganov, Dobrin;
Clark, Justice M.;
Kissick, Haydn T.;
Varghese, Sharlin;
Sanda, Martin G.;
Dranoff, Glenn;
Arredouani, M. Simo;
Balk, Steven P.;
Exley, Mark A.

Publication type:

Article

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2969, doi. 10.1007/s00262-022-03209-1

By:

Tang, Xu-Dong;
Lü, Kui-Lin;
Yu, Jin;
Du, Han-Jian;
Fan, Chao-Qiang;
Chen, Lei

Publication type:

Article

Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2999, doi. 10.1007/s00262-022-03213-5

By:

Jingushi, Kentaro;
Kawashima, Atsunari;
Saito, Takuro;
Kanazawa, Takayuki;
Motooka, Daisuke;
Kimura, Tomonori;
Mita, Masashi;
Yamamoto, Akinaru;
Uemura, Toshihiro;
Yamamichi, Gaku;
Okada, Koichi;
Tomiyama, Eisuke;
Koh, Yoko;
Matsushita, Makoto;
Kato, Taigo;
Hatano, Koji;
Uemura, Motohide;
Tsujikawa, Kazutake;
Wada, Hisashi;
Nonomura, Norio

Publication type:

Article

Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2869, doi. 10.1007/s00262-022-03205-5

By:

Wakiyama, Hiroaki;
Furusawa, Aki;
Okada, Ryuhei;
Inagaki, Fuyuki;
Kato, Takuya;
Furumoto, Hideyuki;
Fukushima, Hiroshi;
Okuyama, Shuhei;
Choyke, Peter L.;
Kobayashi, Hisataka

Publication type:

Article

Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2837, doi. 10.1007/s00262-022-03203-7

By:

Fujiwara, Yu;
Horita, Nobuyuki;
Harrington, Matthew;
Namkoong, Ho;
Miyashita, Hirotaka;
Galsky, Matthew D.

Publication type:

Article

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2913, doi. 10.1007/s00262-022-03202-8

By:

Kreutmair, Stefanie;
Pfeifer, Dietmar;
Waterhouse, Miguel;
Takács, Ferenc;
Graessel, Linda;
Döhner, Konstanze;
Duyster, Justus;
Illert, Anna Lena;
Frey, Anna-Verena;
Schmitt, Michael;
Lübbert, Michael

Publication type:

Article

Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2881, doi. 10.1007/s00262-022-03197-2

By:

Zangari, Brendan;
Tsuji, Takemasa;
Matsuzaki, Junko;
Mohammadpour, Hemn;
Eppolito, Cheryl;
Battaglia, Sebastiano;
Ito, Fumito;
Chodon, Thinle;
Koya, Richard;
Robert McGray, A. J.;
Odunsi, Kunle

Publication type:

Article

Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2929, doi. 10.1007/s00262-022-03192-7

By:

Chovatiya, Nishant;
Kaur, Kawaljit;
Huerta-Yepez, Sara;
Chen, Po-Chun;
Neal, Adam;
DiBernardo, Gabriella;
Gumrukcu, Serhat;
Memarzadeh, Sanaz;
Jewett, Anahid

Publication type:

Article

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2985, doi. 10.1007/s00262-022-03191-8

By:

Moreno, V.;
Calvo, E.;
Middleton, M. R.;
Barlesi, F.;
Gaudy-Marqueste, C.;
Italiano, A.;
Romano, E.;
Marabelle, A.;
Chartash, E.;
Dobrenkov, K.;
Zhou, H.;
Connors, E. C.;
Zhang, Y.;
Wermke, M.

Publication type:

Article

Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 12, p. 2901, doi. 10.1007/s00262-022-03189-2

By:

Kolostova, Katarina;
Pospisilova, Eliska;
Matkowski, Rafal;
Szelachowska, Jolanta;
Bobek, Vladimir

Publication type:

Article

Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 12

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8<sup>+</sup> T‑cells from GzmB mediated self‑destruction.

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.

Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8<sup>+</sup> T cells.

High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.

Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.

Functional expression of CD73 on human natural killer cells.

Natural killer cells and acute myeloid leukemia: promises and challenges.

Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.

Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration.

Targeting tumor extracellular matrix activates the tumor-draining lymph nodes.

Checkpoint-inhibitor induced Polyserositis with Edema.

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes for cancer immunotherapy.

Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.

Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.

Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.

Tcf-1 protects anti-tumor TCR-engineered CD8<sup>+</sup> T-cells from GzmB mediated self-destruction.

Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells.